Les Laboratoires Servier’s two-pronged approach to cancer R&D, focused on immunotherapy and programmed cell death, spans both solid and liquid tumors but homes in on those diseases with a high unmet need.
Talking to Scrip about its pipeline, global head of oncology medical and patient affairs Des Murphy said it addresses rare cancers like leukemia or choleoangiocarcinoma and other more common but still difficult to treat tumors like colorectal cancer
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?